BLA 761146 · Endo Global Aesthetics LTD
Qwo
Collagenase Clostridium Histolyticum-Aaes · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Jul 6, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 6, 2020
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
69
20 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Collagenase Clostridium Histolyticum" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's ContracturesPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01674634 · 715 participants · Start Sep 2012 · Primary completion Jul 2013
Drug: XIAFLEX / XIAPEX · For: Dupuytren's Contracture
Sites: Phoenix, Arizona; Tucson, Arizona; Encinitas, California · 25 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03428750 · 423 participants · Start Feb 5, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Scottsdale, Arizona; Encinitas, California; Long Beach, California · 26 sites in all
- Effectiveness and Safety of EN3835 in the Treatment of Cellulite in WomenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT03446781 · 422 participants · Start Feb 8, 2018 · Primary completion Sep 26, 2018
Drug: EN3835; Placebo · For: Edematous Fibrosclerotic Panniculopathy (Cellulite)
Sites: Glendale, Arizona; North Little Rock, Arkansas; Beverly Hills, California · 25 sites in all
- Study of AA4500 in the Treatment of Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01221597 · 418 participants · Start Sep 2010 · Primary completion Apr 2012
Drug: AA4500; Placebo · For: Peyronie's Disease
Sites: Homewood, Alabama; Phoenix, Arizona; Burbank, California · 34 sites in all
- Study of AA4500 in the Treatment of Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01221623 · 418 participants · Start Oct 2010 · Primary completion Mar 2012
Drug: AA4500; Placebo · For: Peyronie's Disease
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 34 sites in all
- EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Pivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT02724644 · 375 participants · Start Feb 2016 · Primary completion Sep 2016
Drug: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM; Placebo Comparator · For: Edematous Fibrosclerotic Panniculopathy; Cellulite
Sites: Beverly Hills, California; Murrieta, California; Oceanside, California · 16 sites in all
- A Study of AA4500 in Men With Peyronie's DiseasePivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01243411 · 348 participants · Start Nov 2010 · Primary completion Aug 2012
Drug: AA4500 · For: Peyronie's Disease
Sites: Burbank, California; Middlebury, Connecticut; New Haven, Connecticut · 39 sites in all
- Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's DiseasePivotal-lookingStatus unknown
University of CalgaryAcademic, hospital or other
NCT03000114 · 334 participants (planned) · Start Jan 2016 · Primary completion Jan 2021
Drug: XIAFLEX · For: Dupuytren Contracture; Dupuytren's Disease of Finger
Sites: Calgary, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Analysis of Cellulite Treatment Modalities: A Systematic Review.
Lim SK, Gultekin G, Suresan S, et al. · Aesthetic Plast Surg 2025 · Systematic Review, Comparative Study
- What do we know about managing Dupuytren's disease cost-effectively?
Dritsaki M, Rivero-Arias O, Gray A, et al. · BMC Musculoskelet Disord 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy of collagenase Clostridium histolyticum combination therapies for Peyronie's disease: a systematic review and meta-analysis.
Guo Y, Yang Y, Mao Q, et al. · Sex Med Rev 2024 · Systematic Review, Meta-Analysis
- Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.
Smeraglia F, Del Buono A, Maffulli N · Br Med Bull 2016 · Systematic Review
- Collagenase Clostridium Histolyticum-aaes Injections for Volumetric Change of Cellulite Dimples and Gluteal Contouring.
Hartman NN, Almukhtar RM, Wood ES, et al. · Dermatol Surg 2023 · Clinical Trial
- Intralesional Injection Therapy and Atypical Peyronie's Disease: A Systematic Review.
Choi EJ, Xu P, El-Khatib FM, et al. · Sex Med Rev 2021 · Systematic Review
Sponsor: Endo Global Aesthetics LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.